NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today...

Related Keywords

Texas ,United States ,Boston ,Massachusetts ,Michael Miller ,David Ramirez ,Prnewswire Neurobo Pharmaceuticals Inc ,Rx Communications Group ,Neurobo Pharmaceuticals ,Donga St Co ,Nasdaq ,Neurobo Pharmaceuticals Inc ,Two Part Design Provides Optionality ,Interim Analysis ,First Half ,Data Readout Expected ,Second Half ,G Protein Coupled Receptor ,South Texas Research Institute ,Principal Investigator ,Hyung Heon Kim ,Chief Executive Officer ,Non Alcoholic Steatohepatitis ,Private Securities Litigation Reform Act ,Nc ,